These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35979208)

  • 1. Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases.
    Mao J; Yang C; Xin S; Cui K; Liu Z; Wang T; Hu Z; Wang S; Liu J; Song X; Song W
    Front Med (Lausanne); 2022; 9():949567. PubMed ID: 35979208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report.
    Yang R; Chen JX; Luo SH; Chen TT; Chen LW; Huang B
    World J Clin Cases; 2023 Feb; 11(5):1165-1174. PubMed ID: 36874416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.
    Mao S; Zhang J; Guo Y; Zhang Z; Wu Y; Zhang W; Wang L; Geng J; Yan Y; Yao X
    Drug Des Devel Ther; 2019; 13():291-300. PubMed ID: 30666091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
    Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
    Wen F; Lin T; Zhang P; Shen Y
    Front Oncol; 2023; 13():1233196. PubMed ID: 38269021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study.
    Hu J; Chen J; Ou Z; Chen H; Liu Z; Chen M; Zhang R; Yu A; Cao R; Zhang E; Guo X; Peng B; Deng D; Cheng C; Liu J; Li H; Zou Y; Deng R; Qin G; Li W; Wang L; Chen T; Pei X; Gong G; Tang J; Othmane B; Cai Z; Zhang C; Liu Z; Zu X
    Cell Rep Med; 2022 Nov; 3(11):100785. PubMed ID: 36265483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?
    Ghandour RA; Kusin S; Wong D; Meng X; Singla N; Freifeld Y; Bagrodia A; Margulis V; Sagalowsky A; Lotan Y; Woldu SL
    Urol Oncol; 2020 Sep; 38(9):736.e11-736.e18. PubMed ID: 32684514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening logs from a pilot randomized controlled trial of radical cystectomy versus chemoradiation therapy for muscle-invasive bladder cancer.
    Kaushik D; Shi Z; Liss MA; Wang H; Jha RP; Choi BY; Pruthi DK; Ha CS; Mansour AM; Svatek RS
    Urol Oncol; 2020 Jan; 38(1):4.e1-4.e6. PubMed ID: 31676280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy.
    Marcq G; Evaristo G; Kool R; Shinde-Jadhav S; Skowronski R; Mansure JJ; Souhami L; Cury F; Brimo F; Kassouf W
    Eur Urol Open Sci; 2022 Sep; 43():14-21. PubMed ID: 36353066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer.
    Onishi T; Sekito S; Shibahara T; Yabana T
    Urol Oncol; 2021 Feb; 39(2):132.e1-132.e6. PubMed ID: 32792215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.
    Leow JJ; Bedke J; Chamie K; Collins JW; Daneshmand S; Grivas P; Heidenreich A; Messing EM; Royce TJ; Sankin AI; Schoenberg MP; Shipley WU; Villers A; Efstathiou JA; Bellmunt J; Stenzl A
    World J Urol; 2019 Jan; 37(1):61-83. PubMed ID: 30684034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
    Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
    Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
    Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
    J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conservative Management of Muscle Invasive Bladder Cancer in Kidney-Pancreas Transplant Patient.
    Glosser LD; Zakeri BS; Lombardi CV; Ekwenna OO
    Case Rep Transplant; 2022; 2022():5373414. PubMed ID: 35677063
    [No Abstract]   [Full Text] [Related]  

  • 17. The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond.
    Sheybaee Moghaddam F; Dwabe S; Mar N; Safdari L; Sabharwal N; Goldberg H; Daneshvar M; Rezazadeh Kalebasty A
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune checkpoint inhibitors.
    Xu C; Zou W; Wang Y; Liu X; Wang J
    Crit Rev Oncol Hematol; 2023 Nov; 191():104137. PubMed ID: 37717879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.